Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 15/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 15/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 15/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 0.73 |
| ▸ | PRKACG | P22612 | 1/20 | 0.73 |
| ▸ | PRKACB | P22694 | 1/20 | 0.73 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | GMNN | O75496 | 1/20 | 0.68 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tocladesine SCHEMBL1651488 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| Tocladesine SCHEMBL125595 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL9702440 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL5951342 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL29384358 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL14261298 | 0.89 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL29359388 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL9505216 | 0.89 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL2713659 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA | |
| SCHEMBL16079734 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025063845-A1 | DISEASE MODEL | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-03-27 | — | — | WO | claimed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250250538-A1 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2025-08-07 | — | — | US | disclosed |
| CN-120077031-A | Prodrug kit for multitube concurrent chemotherapy | 亚历克斯·祖内克 | 2025-05-30 | — | — | CN | disclosed |
| CN-119997956-A | Pharmaceutical composition and use thereof for treating glioma | 奇默里克斯公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025095107-A1 | METHOD FOR PRODUCING PLATEABLE HEPATOCYTES AND APPLICATION THEREOF | 公立大学法人名古屋市立大学 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025063845-A1 | DISEASE MODEL | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-03-27 | — | — | WO | disclosed |
| CN-119546750-A | Methods for making and using differentiated neural cells | 研究发展基金会 | 2025-02-28 | — | — | CN | disclosed |
| EP-4508196-A1 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | Research Development Foundation (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-116162591-A | Method for efficiently inducing human cells to reprogram into neuron cells in vitro | 广西大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-116144596-A | Method for efficiently inducing human cells to reprogram into neuron cells in vitro | 广西大学 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023074648-A1 | METHOD FOR PRODUCING INTESTINAL ENDOCRINE CELLS, PLURIPOTENT STEM CELL-DERIVED INTESTINAL ENDOCRINE CELLS, MEDIUM OR MEDIUM KIT, AND USE OF THE SAME | 富士フイルム株式会社 | 2023-05-04 | — | — | WO | disclosed |
| EP-4174170-A1 | PRODUCTION METHOD FOR INTESTINAL EPITHELIAL CELLS AND USE THEREFOR | FUJIFILM Corporation (JP) | 2023-05-03 | — | — | EP | disclosed |
| US-20230127775-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | ULTRAGENYX PHARMACEUTICAL INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230126568-A1 | PRODUCTION METHOD FOR INTESTINAL EPITHELIAL CELLS AND UTILIZATION THEREOF | FUJIFILM CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11499963-B2 | Induction of differentiation of induced pluripotent stem cells into intestinal epithelial cells | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2022-11-15 | — | — | US | disclosed |
| WO-2022168908-A1 | PRODUCTION METHOD FOR INTESTINAL TRACT CELLS DERIVED FROM PLURIPOTENT STEM CELLS AND HAVING CRYPT-VILLUS-LIKE STRUCTURES, AND USE THEREOF | 公立大学法人名古屋市立大学 | 2022-08-11 | — | — | WO | disclosed |
| US-20220033780-A1 | METHOD FOR PREPARING INTESTINAL ORGANOID DERIVED FROM PLURIPOTENT STEM CELL | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127775-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | GAA, LIPA, TTR | PDE4A 2517/4885PDE4B 2644/4885PDE4C 2315/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | PDE4A 1506/4885PDE4B 1340/4885PDE4C 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.